Roivant Sciences Ltd at Goldman Sachs Global Healthcare Conference Transcript
Thanks for joining us here at the 43rd Annual Goldman Sachs Global Healthcare Conference. This morning, I'm pleased to welcome the team from Roivant Sciences. We've got Richard Pulik, the Chief Financial Officer; and Mayukh Sukhatme, the Chief Investment Officer at Roivant. So thanks guys for joining us.
Questions & Answers
And maybe just to start, can you provide a brief overview of the company, including some of the key subsidiaries and how that all fits together under this Roivant umbrella?
Sure. So I'll start and then turn it over to Richard too to add. So we're a company that went public last year. We're roughly a -- I think, these days a $2.5 billion or $2.6 billion market cap company, about $2.1 billion in cash, another $300 million in public banks and another $700 million stake
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
